Skip to main content
. 2024 Nov 27;16(23):3980. doi: 10.3390/cancers16233980

Figure 2.

Figure 2

In vitro screening validates selinexor sensitivity across a multitude of TNBC subtypes. (A) IC50 values for MDA-MB-468, MDA-MB-231, MDA-MB-157, BT-549, HCC1-806, HCC-38 and CAL-120, each of which are colored by their TNBC subtype classified by gene profiling. A 10-point dose–response curve was fit to viability data from these cell lines after 72 h treatment with between 0 and 3200 nM selinexor. IC50 values with standard error bars factoring in biological replicates are shown. (B) Percent apoptosis after various selinexor exposure overtime in BT-549 cells. Caspase activation was measured via GFP fluorescence every 8 h following drug treatment for a total of 72 h. (C) Percent apoptosis after various degrees of selinexor exposure overtime in MDA-MB-231 cells. Two-way ANOVA was performed for both panels (B,C). Statistically significant differences were found among treatment groups at a p-value less than 0.05.